The mechanism by which aspirin improves the prognosis of ovarian cancer is usually thought to be related to COX inhibition, with low-dose aspirin primarily inhibiting COX1 and higher doses inhibiting COX2 activity. This evidence concerns the gene PTGS1 and ovarian cancer.